FDA Approves Tocilizumab for Polyarticular JIAFDA Approves Tocilizumab for Polyarticular JIA
The drug is indicated as monotherapy or in combination with methotrexate in children aged 2 years and older with active disease. FDA Approvals
Source: Medscape Rheumatology Headlines - Category: Rheumatology Tags: Rheumatology News Alert Source Type: news